Fujian Haixi Pharmaceuticals Co., Ltd.
福建海西新藥創制股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2637)

RESIGNATION OF NON-EXECUTIVE DIRECTOR AND PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board (the "**Board**") of directors (the "**Directors**") of Fujian Haixi Pharmaceuticals Co., Ltd. (the "**Company**") announces that Mr. Wang Xinkun ("**Mr. Wang**") resigned as a non-executive Director of the Company (the "**Resignation**") with effect from the date on which a new Director is elected at a general meeting of the Company, due to a job transfer. The Board has accepted the Resignation.

Mr. Wang has confirmed to the Board that he has no disagreement with the Board and that there are no other matters in relation to the Resignation that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.

The Board hereby expresses its sincere gratitude to Mr. Wang for his valuable contributions to the Company during his tenure of service.

PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR

The Board is pleased to announce that Mr. Chen Tingze (陳廷澤) ("**Mr. Chen**") has been nominated as a candidate for executive Director of the Company, which has been approved by the Nomination Committee of the Company at its meeting held on 9 July 2026, and by the Board at its meeting held on 15 July 2026. Mr. Chen's term of office will commence on the date of his election at a general meeting of the Company and shall end on the expiry of the term of the second session of the Board.

If appointed, Mr. Chen will not receive any Director's fee but will receive an annual remuneration of approximately RMB640,000 in his capacity as the general manager for domestic marketing of the Company, which is determined with reference to his job responsibilities and prevailing remuneration level in the industry.

The biographical details of Mr. Chen are set out as follows:

Mr. Chen Tingze, aged 43, graduated from University of South China (formerly Hengyang Medical College) in July 2003, majoring in clinical medicine with a junior college diploma, and obtained a bachelor's degree in clinical medicine from Fujian Medical University in January 2012. From July 2004 to May 2006, Mr. Chen served as a resident doctor in the Department of Surgery at Changsha Fangtai Hospital. From May 2006 to February 2008, he served as a resident doctor in the Department of Surgery at Fuzhou Taijiang Hospital. From February 2008 to September 2010, Mr. Chen worked at GlaxoSmithKline (China) Co., Ltd. (葛蘭素史克(中國)有限公司), where he served as a medical representative and senior medical representative in the sales department. From September 2010 to October 2012, he served as regional manager, marketing director, and general manager of Fuzhou Yuzheng Pharmaceutical Technology Co., Ltd. (福州宇正醫藥科技有限公司). From October 2012 to July 2015, he served as regional manager and regional general manager in the sales department of Hisun-Pfizer Pharmaceutical Co. Ltd. (海正輝瑞製藥有限公司). From April 2017 to November 2017, Mr. Chen served as the provincial director for Fujian, Jiangxi, Hunan, and Hubei in the Respiratory and Gastrointestinal Business Unit of the Marketing Center of Chengdu Kanghong Pharmaceutical Group Co., Ltd. (成都康弘藥業集團股份有限公司). From December 2017 to July 2021, he served as regional general manager and regional director of the Marketing Center of Zhejiang Medical Technology Development Co., Ltd.(浙江醫學科技開發有限公司). From July 2021 to March 2022, Mr. Chen served as the general manager of the Marketing Center of Sino Universal Pharma (中寰醫藥集團). Since March 2022, he has served as the Sales Director and General Manager of domestic marketing of the Company. Since June 2025, Mr. Chen has concurrently served as a director and general manager of Haixi Pharmaceuticals (Fuzhou) Co., Ltd. (海西新藥創制(福州)有限公司).

Mr. Chen has made a capital contribution of RMB2.5 million to Xiamen Jindonghong Venture Capital Partnership (Limited Partnership), representing 1.9231% of its total capital contribution. In addition, he has made a capital contribution of RMB1.0 million to Xiamen Jindongshi Venture Capital Partnership (Limited Partnership), representing 2.3529% of its total capital contribution. Xiamen Jindonghong Venture Capital Partnership (Limited Partnership) holds 5.6984% of the total share capital of the Company, and Xiamen Jindongshi Venture Capital Partnership (Limited Partnership) holds 4.9863% of the total share capital of the Company.

As at the date of this announcement, save as disclosed above, Mr. Chen (i) does not hold any directorships in any other listed companies in Hong Kong or overseas or other major appointments and qualifications in the past three years; (ii) does not hold any other position in the Company or its subsidiaries; (iii) has no relationship with any Director, senior management, substantial shareholder or controlling shareholder of the Company; and (iv) does not have any interest in the shares of the Company or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

As at the date of this announcement, save as disclosed above, there are no other matters in connection with Mr. Chen's appointment that need to be brought to the attention of the shareholders of the Company, nor any information that is required to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited.

GENERAL

An ordinary resolution will be proposed at the extraordinary general meeting of the Company for the shareholders of the Company to consider and, if thought fit, approve the proposed appointment of executive Director.

A circular containing, among other things, details of the proposed appointment of executive Director, together with a notice of the extraordinary general meeting, will be despatched to the shareholders of the Company as soon as practicable.

By order of the Board
Fujian Haixi Pharmaceuticals Co., Ltd.
Dr. Kang Xinshan
Executive Director, Chairman and General Manager

Hong Kong, 15 July 2026

As of the date of this announcement, the Board comprises (i) Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming and Mr. Li Junqing as executive Directors; (ii) Mr. Wang Xinkun and Mr. Xu Dong as non-executive Directors; and (iii) Ms. Wang Shan Shan, Ms. Pu Meiting and Mr. Lin Bin as independent non-executive Directors.